The expansion includes the addition of an aseptic syringe filling line, which will help BPS to meet the increasing demand for this delivery platform in Europe and the US
Baxter has announced the expansion of sterile fill/finish manufacturing facility in Germany. (Credit: MasterTux from Pixabay)
Baxter International is set to invest up to $100m to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany.
Baxter’s business unit BioPharma Solutions (BPS) operates the sterile fill/finish manufacturing facility.
BPS supports pharmaceutical and biotech firms in the development and contract manufacturing of drug products for parenteral (injectable) pharmaceuticals.
Baxter intends to begin construction on the new manufacturing facility next year. Work on the project is expected to complete in 2024.
The strategic investment will allow BPS to expand its manufacturing footprint and add advanced equipment to achieve stability and enhance shelf life through lyophilisation (freeze drying).
The expansion also includes the addition of an aseptic syringe filling line, which will help BPS to meet the increasing demand for this delivery platform in Europe and the US.
Pre-filled syringes are expected to hold the potential to minimise microbial contamination, as well as reduce medication dosing errors during medication preparation.
Baxter BioPharma Solutions general manager Marie Keeley said: “Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years.
“By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future.”
With over 60 years of experience, Baxter’s Halle/Westfalen site manufactures cytotoxic and highly potent drugs.
The facility, which was earlier expanded in 2015, also features wider sterile manufacturing capabilities. It is also involved in multiple collaborations to deliver manufacturing services for Covid-19 vaccines.
In March this year, Baxter collaborated with Moderna for fill/finish manufacturing of the Covid-19 vaccine in the US.